Figure 4.

Non-inferiority for 23-valent pneumococcal polysaccharide vaccine (PPV23) IgG geometric mean concentrations (GMC) ratios and seroconversion rate of co-administration versus separate administration. Blood samples were collected 28 days after each group received the PPV23 vaccine. The PPV23 IgG antibody concentration was determined using an in-house ELISA. The PPV23 IgG GMT ratios of the 18-59 age group (A) and ≥60 age group (C) were compared between the co-administration groups and the SARS-CoV-2+IIV4/PPV23 group. The differences in seroconversion rates of the 18-59 age group (B) and ≥60 age group (D) were compared between the co-administration groups and the separate administration group. The dashed lines represent the 95% CI lower boundary of 0.5 for GMT ratios and -10% for the seroconversion rate differences.